<DOC>
	<DOCNO>NCT00537966</DOCNO>
	<brief_summary>Aim study : To describe epidemiology , longitudinally follow , test effect early antiretroviral treatment investigate early event virus-host interaction patient document acute recent HIV-1 infection Zurich . Study design : This open label , non-randomized , observational , single center study University Hospital Zurich , Division Infectious Diseases Hospital Epidemiology . We aim enrol approximately 300 patient 10 year period . All patient fulfill inclusion criterion document acute recent HIV infection participate study . Patients offer early combination antiretroviral treatment ( cART ) , treatment start fall within 90 day diagnosis acute HIV-infection . After one year suppress HIV-plasma viremia ( &lt; 50 copies/ml ) patient chose stop cART . Patients chosen undergo early-cART , respectively stop cART one year follow total 5 year . Viral setpoints reach treatment interruption compare historic control control group receive cART acute infection . A battery virological immunological assay perform blood sample obtain well understand early virus-host interaction , think play key role HIV-pathogenesis research . Summary : In summary , study provide comprehensive knowledge early HIV-infection regard epidemiology , impact early-cART course disease form base variety translational research project address early key pathogenesis event virus host , relevant course disease , transmission , development vaccine new treatment strategy . - Trial medicinal product</brief_summary>
	<brief_title>Characterization Acute Recent HIV-1 Infections Zurich : Long-term Observational Study</brief_title>
	<detailed_description>By end 2008 , enrol 200 patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : A ) Acute HIV1 infection , define : Acute retroviral syndrome [ 78 ] ( ARS ) negative indeterminate Westernblot presence positive p24 Ag and/or detectable plasma HIV1 RNA Documented seroconversion without symptom within 90 day . B ) Recent HIV1 infection , define : Possible ARS , positive Westernblot detectable HIVRNA , negative HIVgp120 avidity [ 82 , 83 ] , respectively detuned assay [ 84 ] . Documented acute HIV1 infection , however , referral center 90 day presume date infection . Exclusion criterion : Hemoglobin &lt; 10 g/dl ( men ) &lt; 9 g/dl ( woman ) time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Primary HIV Infection</keyword>
</DOC>